Sentences with phrase «increased their dividends year over»

The S&P 500 Dividend Aristocrats index selects companies in the S&P 500 that have increased their dividends year over year for at least 25 consecutive years.

More than half a century the company increased its dividends year over year.

A better approach is to buy Dividend Aristocrats, quality stocks that are listed in the S&P 500 and that have increased their dividends every year over the past 25 years.

Not exact matches

This Toronto - based property and casualty insurance company has increased its dividend by more than 50 % over the past three years while its stock price has climbed from $ 35 to $ 62.

With this Armonk, N.Y. — based technology giant, you're getting a company that's increased its dividend for 18 straight years and has a proven that it can grow its earnings over the long term.

I am pleased to announce that our Board of Directors declared a 7 % increase in our quarterly cash dividend to $ 0.77 per share, marking 14 consecutive years of dividend increases with a compound annual growth rate of about 10 % over that period.

At the same time, the company has increased its dividend by 33 % over the past five years, yet its payout ratio is a paltry 9 %.

It has increased its dividend five times over the past five years.

The group chairman, Jose Vinals, said in the same statement that the board «understands the importance of the ordinary dividend to shareholders and intends to increase the full year dividend per share over time.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The «Dividend Aristocrats» are a list of blue chip companies in the S&P 500 that have demonstrated a consistent increase in dividend payouts over thDividend Aristocrats» are a list of blue chip companies in the S&P 500 that have demonstrated a consistent increase in dividend payouts over thdividend payouts over the years.

-LSB-...] increasing its payout over the last seven years and is just three years away from making it to the Dividend Achievers list.

Instead, it looks for TSX - listed companies that have at least $ 300 mln in market cap and have paid and increased their dividends over each of the last five years.

The Minneapolis - based financial services company also announced a dividend of 90 cents per share, an 8 percent increase over the previous quarter and the 11th quarterly dividend increase in the last nine years.

Also, to be included in the Index, companies must have paid and increased thier dividends over each of the last five years.

The great news is that my dividend income has increase modestly over the past three years but is still far from my goal.

CSCO has increased its quarterly dividend from $ 0.14 to $ 0.29 over the past five years, or 16 % compounded annually.

Some analysts predict the company could send as much as $ 180 billion to investors through stock buybacks and dividend increases over the next two and a half years, on top of the $ 300 billion it has already authorized.

A value over 1.0 suggests that the dividend growth rate has been increasing as the 5 year rate is higher than the 10 year rate.

Over the past 5 years, BEP has maintained an 8 % FFO / units CAGR while increasing its dividends by 6 %.

We have increased our dividends by 100 % over the last 3 years, which speaks to the consistent cash flow we generate and our intent to return more capital to shareholders through dividends.

Stocks of companies such as Coca Cola, ExxonMobil, Chevron, Nestlé, Novartis, Roche and Unilever with a long track record of increasing their dividends have played an important role in my portfolio over the last years.

Outside analysts suggest they will increase their dividend at a faster rate over the next two years and possibly pay a one time special dividend.

• Stellar dividend resume: Decent yield at 2.9 %; excellent dividend growth rate of 20 % over the past 5 years; upcoming increase of 14 % in December; strong dividend safety, protected by very good cash flow; and 44 - year streak of increasing dividends.

Colgate - Palmolive Company (NYSE: CL) is a «dividend king,» having increased its dividend annually for over 50 straight years — 53, to be exact.

CubeSmart has an impressive dividend growth track record, increasing payouts by 28 % CAGR over the last five years and by 23 % in the last year itself.

Richard Kinder had telegraphed, vehemently so, 10 % dividend increases annually over the next five years.

• Good dividend resume: Yield 3.0 %; stated commitment to dividend; 15 straight years of increases; strong dividend growth record (10 % per year over past 5 years); and strong dividend safety.

Over 150 dividend stocks have increased their dividend for at least 20 consecutive years, significantly more than the 51 Dividend Arisdividend stocks have increased their dividend for at least 20 consecutive years, significantly more than the 51 Dividend Arisdividend for at least 20 consecutive years, significantly more than the 51 Dividend ArisDividend Aristocrats.

Dominion is a Dividend Achiever (meaning they have continuously paid and increased dividends over 10 years).

• Excellent on certain dividend categories, including 43 straight years of increases, low payout ratio, and highest yield ever available • Declining number of shares over the past 10 years makes each remaining share worth a higher percentage of the company.

If someone handed me $ 10,000,000 with the imperative to construct a portfolio that will, comprehensively, make money in all environments, increase wealth by at least 5 % in excess of the rate of inflation over the long term, and do it in a way that the total dividends paid out would be greater each year, these are the companies I would choose.

Furthermore, SNA has increased its dividend consecutively over the last nine years.

Twelve of our companies, just over 20 % of our holdings, used their cash flow to achieve all four goals: they increased the dividend, reduced the share count, made an acquisition and still ended the year with a stronger balance sheet.

An improving balance sheet and consistent cash generation from its operations have allowed management to reward investors with annual dividend increases over the past three years.

Based on the data below, for each 1 % increase in the 10 - year U.S. Treasury yield, STORE capital's dividend yield can be expected to rise by about 1.47 %, meaning the share price would be expected to decline (perhaps somewhat meaningfully) over the short - term.

The yield is over 3 %, the growth rate is phenomenal, the payout ratio is a manageable 46 % and QCOM has increased the dividend 13 consecutive years.

The first screen looks for companies with above - average dividend yields that have also maintained or increased their dividends over the past five years.

And because many of the companies he owned had a tendency of increasing their dividend each year, his passive income stream was poised to grow larger and larger over time.

As for dividend growth, CU has posted an increase consecutively for over forty years.

Assumes: 7 % annualized reinvested dividends over five years, with 2 % annual property value increases *

For fiscal year 2014 BlackRock is on track to pay $ 7.72 per share in dividends a 14.8 % increase over fiscal year 2013.

Additionally, there are eight constituents with over 55 consecutive years of dividend increases.

Walgreens Boots Alliance has paid out dividends for over 81 years and began increasing dividends 38 years ago, in 1976.

The initial DGR is much lower than what's transpired over the last five years; it's also much lower than the most recent dividend increase.

We trace increases over 5 years and more, to get a timely reading on the company's commitment to dividend increases.

The last two columns illustrate how that DGR has increased the dollar - and - cents amount of the annual dividend over the 10 years from 2002 - 2012.

That 8 % dividend increase really gave Jason a 12 % year over year increase when you mix dividend growth with dividend reinvestment.

And this biotech firm is proving its desire to grow its dividend aggressively; the company has increased its dividend at an annual rate of 29.9 % over the last three years, with its most recent dividend increase being right in that neighborhood.

The annual dividend has increased over each of the last six years and the company has not reduced its annual dividend payment;